<DOC>
	<DOCNO>NCT00629473</DOCNO>
	<brief_summary>This Phase 1 clinical trial examine safety , pharmacokinetics pharmacodynamics escalate dos proteasome inhibitor NPI-0052 patient advanced malignancy include solid tumor , lymphoma , leukemias multiple myeloma . By inhibit proteasomes NPI-0052 prevents breakdown protein involve signal transduction , block growth survival cancer cell .</brief_summary>
	<brief_title>Phase 1 Clinical Trial Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Karnofsky Performance Status ( KPS ) &gt; 70 % . Histologicallyconfirmed advance malignancy standard , approve therapy available . Adequate renal , liver , pancreatic hematologic function Signed informed consent ( sample IC form provide Appendix A ) . Exclusion Criteria Administration chemotherapy , biological , immunotherapy investigational agent ( therapeutic diagnostic ) within 28 day Patients require GCSF and/or platelet support screen likely require GCSF and/or platelet support duration clinical trial . Patients ongoing coagulopathies and/or take anticoagulant Patients receive intrathecal therapy . Known brain metastasis . Preexisting adrenal insufficiency ; concomitant therapy replacement corticosteroid . Preexisting acute chronic pancreatitis . Significant cardiac disease . Pregnant breastfeed woman . Concurrent , active secondary malignancy patient receive therapy . ( Lymphoma patient diagnosis potentially hormonesensitive tumor without evidence disease second malignancy may continue receive hormonal therapy ) . Patients proteinuria Grade 2 great Active uncontrolled bacterial fungal infection require systemic therapy ; infection require parenteral antibiotic . Patients know HIV positive active Hepatitis A , B , C infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>leukemia ( inc. CLL )</keyword>
	<keyword>lymphoma</keyword>
	<keyword>cutaneous lymphoma</keyword>
	<keyword>marginal zone lymphoma</keyword>
	<keyword>advanced malignancy without standard treatment option</keyword>
</DOC>